ARTICLE | Distillery Therapeutics
Neurology
February 28, 2017 11:53 PM UTC
Patient sample and mouse studies suggest inhibiting CSNK2A2 could help treat HD. Levels of CSNK2A2 were higher in striatal tissue samples from HD patients and striatal and gastrocnemius muscle tissue ...
BCIQ Company Profiles